Cara Therapeutics reported $-30876000 in EBIT for its second fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -43709000 23.06M
Acelrx Pharmaceuticals ACRX:US $ -9684000 20K
Aerie Pharmaceuticals AERI:US $ -31501000 2.72M
Antares Pharma ATRS:US $ 6.79M 1.4M
Arena Pharmaceuticals ARNA:US $ -144391000 12.4M
Cara Therapeutics CARA:US $ -30876000 7.32M
Chugai Pharma 4519:JP 96.71B 32.75B
Endo International Ordinary Shares ENDP:US $ 195.54M 19.6M
Halozyme Therapeutics HALO:US $ 93.05M 42.31M
Horizon Pharma HZNP:US 213.77M 303.22M
JAZZ PHA JAZZ:US -69590000 231.71M
Johnson & Johnson JNJ:US $ 7033M 2723M
Neurocrine Biosciences NBIX:US $ 67.8M 36.3M
Pacira Pharmaceuticals PCRX:US $ 34.99M 13.68M
Pain Therapeutics PTIE:US $ -5138000 1.6M
Pfizer PFE:US $ 6662M 905M
Redhill Biopharma RDHL:US -24886000 6.73M
Revance Therapeutics RVNC:US $ -70337000 325K
Supernus Pharmaceuticals SUPN:US $ 34.11M 20.9M
Teva Pharmaceutical Industries TEVA:US 829M 35M
Vanda Pharmaceuticals VNDA:US $ 12.37M 2.03M